Analysis of clinical characteristics and outcomes of ALK positive (ALK plus ) patients treated with ALK inhibitors (ALKi).

被引：0

作者：

Perez, Susana Cedres

Aranda, Nuria Pardo

Navarro, Alejandro

Marti, Alex Martinez

de Castro, Ana Maria Martinez

Cabrera, Guadalupe

Vilaro, Marta

Carbonell, LLuisa

de la Fuente, Iris

Piera, Adelaida

Martinez, Lidia

Hernandez-Losa, Javier

Sansano, Irene

Felip, Enriqueta

机构：

[1] Vall dHebron Univ Hosp, Barcelona, Spain

[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain

[3] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[4] Inst Salvadoreno Seguro Social, San Salvador, El Salvador

[5] Vall dHebron Inst Oncol, Oncol Data Sci OdysSey Grp, Barcelona, Spain

[6] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain

[7] Vall dHebron Univ, Barcelona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.e20550

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e20550

引用

页数：2

共 50 条

[1] ALK Inhibitors in the Treatment of ALK Positive NSCLC
Khan, Muhammad
Lin, Jie
Liao, Guixiang
Tian, Yunhong
Liang, Yingying
Li, Rong
Liu, Mengzhong
Yuan, Yawei
FRONTIERS IN ONCOLOGY, 2019, 8
[2] Analysis of resistance mechanisms to ALK kinase inhibitors in ALK plus NSCLC patients.
Doebele, Robert Charles
Aisner, Dara L.
Le, Anh T.
Berge, Eamon M.
Pilling, Amanda B.
Kutateladze, Tatiana G.
Weickhardt, Andrew James
Franklin, Wilbur A.
Varella-Garcia, Marileila
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[3] Evolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs).
Gainor, Justin F.
Friboulet, Luc
Katayama, Ryohei
Awad, Mark M.
Lockerman, Elizabeth L.
Schultz, Katherine
Mahmood, Sidra
Nishio, Makoto
Yanagitani, Noriko
Sequist, Lecia V.
Mino-Kenudson, Mari
Engelman, Jeffrey A.
Shaw, Alice Tsang
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[4] ALK Inhibitor Sequencing and Outcomes Among ALK-Positive (ALK plus ) NSCLC Patients in the US Community Oncology Setting
Waterhouse, D.
Espirito, J.
Chioda, M.
Baidoo, B.
Mardekian, J.
Robert, N.
Masters, E.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S560
[5] A Retrospective Analysis of the Efficacy and Safety of ALK Inhibitors in ALK-Positive Lung Cancer Patients
Komiya, Kazutoshi
Nakamura, Tomomi
Kurihara, Yuki
Hirakawa, Haruki
Sadamatsu, Hironori
Nakashima, Chiho
Umeguchi, Hitomi
Takeda, Yuji
Kimura, Shinya
Sueoka-Aragane, Naoko
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1178 - S1179
[6] Outcomes of ALK plus non-small cell lung cancer (NSCLC) patients treated with ALK inhibitors in the clinical trial setting and in a referral Institution.
Rojo, Ana Matres
Felip, Enriqueta
Dienstmann, Rodrigo
Garces, Victor Navarro
Viaplana, Cristina
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors
Valery, Marine
Facchinetti, Francesco
Malka, David
Ducreux, Michel
Friboulet, Luc
Hollebecque, Antoine
DIGESTIVE AND LIVER DISEASE, 2021, 53 (12) : 1664 - 1665
[8] ALK plus NSCLC ALK Inhibitors symbolize Progress in Cancer Medicine
Kohl, Angelika
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (7-8) : 435 - 435
[9] Brigatinib in Japanese ALK positive NSCLC patients previously treated with ALK tyrosine kinase inhibitors: J-ALTA.
Yoshida, Tatsuya
Nishio, Makoto
Kumagai, Toru
Hida, Toyoaki
Toyozawa, Ryo
Shimokawaji, Tadasuke
Goto, Koichi
Nakagawa, Kazuhiko
Ohe, Yuichiro
Yamamoto, Nobuyuki
Kudou, Kentarou
Asato, Takayuki
Zhang, Pingkuan
Seto, Takashi
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC).
Dagogo-Jack, Ibiayi
Santini, Fernando
Eng, Juliana
Yeap, Beow Y.
Izar, Benjamin
Chin, Emily
Litvak, Anya
Jones, David Randolph
Kris, Mark G.
Shaw, Alice Tsang
Gainor, Justin F.
Chaft, Jamie E.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →